Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico
- Open Access
- 01-12-2024
- Type 2 Diabetes
- Research
Published in:
- Authors
- Devany Paola Morales-Rodriguez
- Arnulfo González-Cantú
- Arnulfo Garza-Silva
- Andrea Rivera-Cavazos
- Iván Francisco Fernández-Chau
- Andrea Belinda Cepeda-Medina
- Miguel Angel Sanz-Sánchez
- Gerardo Francisco del Rio-Parra
- María Angelina Torres-Fuentes
- Miguel Assael Rodriguez-Puente
- Maria Elena Romero-Ibarguengoitia
- Published in
- Diabetology & Metabolic Syndrome | Issue 1/2024
Abstract
Background
The SARS-CoV-2 pandemic brought a radical shift in the healthcare system and suboptimal care for vulnerable patients, such as those with Type 2 Diabetes Mellitus (T2D). Therefore, we compared metabolic control and macro/microvascular complications of patients with T2D before and throughout the three-year SARS-CoV-2 pandemic.
Research design and methods
A retrospective observational cohort of subjects with T2D studied from 2018 to 2022 in Northern Mexico was treated by a dynamic multidisciplinary team. Levels of Glycated hemoglobin (HbA1c), fasting serum glucose (FG), LDL-Cholesterol (LDL-C), blood pressure (BP), albuminuria, triglycerides, Body Mass Index (BMI), and FIB-4 score, micro and macrovascular complications were evaluated.
Results
A total of 999 patients were studied, 51.7% males with a mean (SD) age of 60.1 (12.7) years. Adequate glycemic control based on HbA1c increased by 15.2% and 42.3% in FSG (p < 0.001) between the beginning 2018 and the end of 2022. LDL-C control decreased by 5.1% between 2018 and 2022 (p < 0.001). Systolic BP control decreased by 2.6% (p < 0.001), whereas diastolic BP control increased by 1.8% (p = 0.01) between 2018 and 2022. Albuminuria control increased by 8.5% (p = 0.002). When comparing the Area Under the Curve (AUC) of metabolic parameters between patients who developed SARS-CoV-2 vs. those who did not, AUC was statistically higher in those who developed SARS-CoV-2 (p < 0.05). Diabetic neuropathy was the most prevalent microvascular complication (n = 35; 3.6%); ischemic heart disease was the most frequent macrovascular complication (n = 11;1.1%).
Conclusions
A multidisciplinary dynamic team that adapts to the pandemic SARS-CoV-2 maintains and increases metabolic control in subjects with type 2 diabetes in Mexico. This represents a low percentage of chronic complications. The AUC of metabolic parameters of subjects with SARS-CoV-2 infection is higher, reflecting more variability in metabolic control.
Graphical Abstract
Advertisement
- Title
- Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico
- Authors
-
Devany Paola Morales-Rodriguez
Arnulfo González-Cantú
Arnulfo Garza-Silva
Andrea Rivera-Cavazos
Iván Francisco Fernández-Chau
Andrea Belinda Cepeda-Medina
Miguel Angel Sanz-Sánchez
Gerardo Francisco del Rio-Parra
María Angelina Torres-Fuentes
Miguel Assael Rodriguez-Puente
Maria Elena Romero-Ibarguengoitia
- Publication date
- 01-12-2024
- Publisher
- BioMed Central
- Keywords
-
Type 2 Diabetes
SARS-CoV-2 - Published in
-
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996 - DOI
- https://doi.org/10.1186/s13098-024-01318-8
This content is only visible if you are logged in and have the appropriate permissions.
